PT  - JOURNAL ARTICLE
AU  - GeurtsvanKessel, Corine H.
AU  - Okba, Nisreen M.A.
AU  - Igloi, Zsofia
AU  - Embregts, Carmen W.E.
AU  - Laksono, Brigitta M.
AU  - Leijten, Lonneke
AU  - Rahamat-Langendoen, Janette
AU  - van den Akker, Johannes P.C.
AU  - van Kampen, Jeroen J.A.
AU  - van der Eijk, Annemiek A.
AU  - van Binnendijk, Rob S.
AU  - Haagmans, Bart
AU  - Koopmans, Marion
TI  - Towards the next phase: evaluation of serological assays for diagnostics and exposure assessment
AID  - 10.1101/2020.04.23.20077156
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.23.20077156
4099  - http://medrxiv.org/content/early/2020/04/29/2020.04.23.20077156.short
4100  - http://medrxiv.org/content/early/2020/04/29/2020.04.23.20077156.full
AB  - The world is entering a new era of the COVID-19 pandemic in which there is an increasing call for reliable antibody testing. To support decision making on the deployment of serology for either population screening or diagnostics, we present a comprehensive comparison of serological COVID-19 assays. We show that the assay detecting total immunoglobulins against the receptor binding domain of SARS CoV- 2, had optimal characteristics for antibody detection in different stages of disease.Competing Interest StatementThe authors have declared no competing interest.Funding Statementno external funding was receivedAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesall data is included in the manuscript